Allergy drug dupilumab tested as potential hair loss treatment

NCT ID NCT05551793

Recruiting now Disease control Sponsor: Emma Guttman Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dupilumab, a drug used for allergies and eczema, can help regrow hair in people with moderate-to-severe alopecia areata who also have allergies or high IgE levels. Participants receive weekly injections of dupilumab or a placebo for 48 weeks, followed by an additional 48 weeks of dupilumab for all. The main goal is to measure changes in scalp hair loss using the SALT score.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dupilumab
What this could lead to: If successful, dupilumab could offer a new treatment option for people with alopecia areata who also have allergies or high IgE levels.
What could go wrong: This is a Phase 2 trial with a small number of participants. The drug may not work for everyone, and side effects like injection reactions or eye inflammation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
UR Dermatology at College Town
RECRUITING

Rochester, New York, 14620, United States
University of California, Irvine
RECRUITING

Irvine, California, 92697, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.